Published on November 7, 2016
Promising new treatments such as CAR-T therapies are offering hope to cutaneous non-Hodgkin lymphoma patients. Traditional therapies focus on treating the skin whether it is radiation, chemotherapy or steroids that are applied topically. The cure approach is an allogeneic transplant, but this option has usually a high morbidity. New CAR-T therapies provide a glimmer of hope for the near future. This interview with Steven Rosen, MD, Provost and Chief Scientific Officer at City of Hope was recorded at the 14th International Workshop on Non-Hodgkin Lymphoma in San Diego (CA) (iwnhl.org).